Clinical Pipeline
Shattuck’s lead partnered compound entered the clinic in April 2019, and its lead wholly-owned compound entered the clinic in August of 2020.
To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 300 bi-functional fusion protein drug candidates, two of which are currently in clinical trials for the treatment of life-threatening and debilitating diseases. The two lead ARC molecules are designed to block checkpoint molecules that limit the immune system (PD-1 and CD47) while simultaneously stimulating T-cell receptors to initiate an immune response (OX40 or CD40). Shattuck’s lead partnered asset, SL-279252 (PD1-Fc-OX40L), has advanced to the clinic in less than two years and is currently enrolling patients at five sites across the United States, Canada, and Europe. Shattuck’s internal lead asset, SL-172154 (SIRPα-Fc-CD40L), will be enrolling patients in its clinical trials during the second half of 2020.
Program | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|
SL-172154 - I.V. SIRPα-Fc-CD40L | Phase 1 Study Open | |||||
SL-172154 - I.T.I. SIRPα-Fc-CD40L | Phase 1 Study Open | |||||
SL-279252 PD1-Fc-OX40L | ![]() | Enrolling Phase 1 / Data Expected Late 2021 |
Drug | Indication | Stage |
---|---|---|
SL-172154 - I.V. | SIRPα-Fc-CD40L | Phase 1 |
SL-172154 - I.T.I. | SIRPα-Fc-CD40L | Phase 1 |
SL-279252 | PD1-Fc-OX40L | Phase 1 |
Discovery and Preclinical Pipeline
With over 300 bi-functional fusion protein compounds created to date, Shattuck has a robust pipeline of therapeutic candidates for the treatment of cancer and autoimmune disease.
Program | Discovery | Lead Selection | Non-Clinical Development | Manufacturing | Status | ||
---|---|---|---|---|---|---|---|
ARC PLATFORM - R&D ONCOLOGY | |||||||
SL-115154 CSF1R-Fc-CD40L | ![]() | Manufacturing | |||||
SL-9258 TIGIT-Fc-LIGHT | Manufacturing | ||||||
SL-279137 PD1-Fc-41BBL | Non-Clinical Development | ||||||
SL-6159 CD86-Fc-NKG2a | Lead Selection | ||||||
Multiple Multiple Undisclosed | Lead Selection | ||||||
ARC PLATFORM - R&D AUTOIMMUNE | |||||||
Multiple Multiple Undisclosed | Lead Selection | ||||||
GADLEN PLATFORM | |||||||
Multiple Multiple Undisclosed | Lead Selection |
Drug | Indication | Stage | ARC PLATFORM - R&D ONCOLOGY |
---|---|---|
SL-115154 | CSF1R-Fc-CD40L | Manufacturing |
SL-9258 | TIGIT-Fc-LIGHT | Manufacturing |
SL-279137 | PD1-Fc-41BBL | Non-Clinical Development |
SL-6159 | CD86-Fc-NKG2a | Lead Selection |
Multiple | Multiple Undisclosed | Lead Selection |
ARC PLATFORM - R&D AUTOIMMUNE |
||
Multiple | Multiple Undisclosed | Lead Selection |
GADLEN PLATFORM |
||
Multiple | Multiple Undisclosed | Lead Selection |